Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 with Azacitidine in Myeloid Malignancies
NCT07011186Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3909 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2024; status: recruiting.
02
Drugs
TQB3909
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07011186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011186.